Highbridge Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Highbridge Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,000	Closed	-$1.25M	–	250
2019 Q1	$1.25M	Sell	10,000 -3,750	-27%	-$466K	0.04%	256
2018 Q4	$1.55M	Buy	13,750 +3,750	+38%	+$580K	0.05%	245
2018 Q3	$2.14M	Buy	+10,000	New	+$2.51M	0.05%	330
2015 Q3	–	Sell	-999	Closed	-$78K	–	1725
2015 Q2	$78K	Sell	999 -3,209	-76%	-$269K	﹤0.01%	1345
2015 Q1	$286K	Sell	4,208 -7,133	-63%	-$612K	﹤0.01%	1149
2014 Q4	$1.05M	Sell	11,341 -746	-6%	-$77.1K	0.01%	637
2014 Q3	$1.27M	Buy	12,087 +11,521	+2,036%	+$1.6M	0.02%	588
2014 Q2	$81K	Buy	+566	New	+$82.7K	﹤0.01%	1012
2013 Q3	–	Sell	-926	Closed	-$162K	–	1419
2013 Q2	$162K	Buy	+926	New	+$241K	﹤0.01%	1209

Other funds holding MDGL

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Highbridge Capital Management's MDGL Position: Q2 2019 in Review

Highbridge Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2019, closing a stake of 10,000 shares — an estimated $1.25M sold.

Highbridge Capital Management first reported a position in MDGL in Q2 2013 and held it in 9 quarters. The position peaked at $2.14M in Q3 2018. 116 funds tracked by Wall St. Rank hold MDGL as of Q2 2019.

Highbridge Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Highbridge Capital Management sold 10,000 Madrigal Pharmaceuticals shares in Q2 2019, an estimated $1.25M.
Highbridge Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Highbridge Capital Management's Madrigal Pharmaceuticals position peaked at $2.14M in Q3 2018.
116 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2019.

Based on Highbridge Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.